IDEAYA to present Phase 1 expansion data for IDE397 in MTAP-deletion NSCLC/urothelial at EORTC-NCI-AACR

IDEAYA Biosciences, Inc.

Phase 1 expansion results for IDE397 (MAT2A inhibitor) in MTAP-deletion NSCLC and urothelial cancer to be presented as late-breaker oral on Oct 25.
Presenter is Dr. Benjamin Herzberg, Columbia University; abstract #501 LBA.
Additional poster: preclinical data for MAT2A + PRMT5 combination in MTAP-deleted tumors (poster PB204).
Additional poster: preclinical data for IDE161, a PARG inhibitor targeting solid tumors (poster PB337).
EORTC-NCI-AACR Symposium in Barcelona, Oct 23-25, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.